169 related articles for article (PubMed ID: 30600607)
21. Study of cohort-specific consent and patient control in phase I cancer trials.
Daugherty CK; Ratain MJ; Minami H; Banik DM; Vogelzang NJ; Stadler WM; Siegler M
J Clin Oncol; 1998 Jul; 16(7):2305-12. PubMed ID: 9667244
[TBL] [Abstract][Full Text] [Related]
22. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
23. Precision medicine ethics: selected issues and developments in next-generation sequencing, clinical oncology, and ethics.
Fiore RN; Goodman KW
Curr Opin Oncol; 2016 Jan; 28(1):83-7. PubMed ID: 26569425
[TBL] [Abstract][Full Text] [Related]
24. Speaking genomics to parents offered germline testing for cancer predisposition: Use of a 2-visit consent model.
Johnson LM; Sykes AD; Lu Z; Valdez JM; Gattuso J; Gerhardt E; Hamilton KV; Harrison LW; Hines-Dowell SJ; Jurbergs N; McGee RB; Nuccio R; Ouma AA; Pritchard M; Quinn EA; Baker JN; Mandrell BN; Nichols KE
Cancer; 2019 Jul; 125(14):2455-2464. PubMed ID: 30901077
[TBL] [Abstract][Full Text] [Related]
25. Integrating next-generation sequencing into pediatric oncology practice: An assessment of physician confidence and understanding of clinical genomics.
Johnson LM; Valdez JM; Quinn EA; Sykes AD; McGee RB; Nuccio R; Hines-Dowell SJ; Baker JN; Kesserwan C; Nichols KE; Mandrell BN
Cancer; 2017 Jun; 123(12):2352-2359. PubMed ID: 28192596
[TBL] [Abstract][Full Text] [Related]
26. Identifying components in consent information needed to support informed decision making about trial participation: An interview study with women managing cancer.
Abhyankar P; Velikova G; Summers B; Bekker HL
Soc Sci Med; 2016 Jul; 161():83-91. PubMed ID: 27261532
[TBL] [Abstract][Full Text] [Related]
27. The Architecture of a Precision Oncology Platform.
Laganà A
Adv Exp Med Biol; 2022; 1361():1-22. PubMed ID: 35230680
[TBL] [Abstract][Full Text] [Related]
28. Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations.
Oberg JA; Ruiz J; Ali-Shaw T; Schlechtweg KA; Ricci A; Kung AL; Chung WK; Appelbaum PS; Glade Bender JL; Levine JM
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913997
[TBL] [Abstract][Full Text] [Related]
29. Parents' expectations, preferences, and recall of germline findings in a childhood cancer precision medicine trial.
McGill BC; Wakefield CE; Tucker KM; Daly RA; Donoghoe MW; Vetsch J; Warby M; Fuentes-Bolanos NA; Barlow-Stewart K; Kirk J; Courtney E; O'Brien TA; Marshall GM; Pinese M; Cowley MJ; Tyrrell V; Deyell RJ; Ziegler DS; Hetherington K
Cancer; 2023 Nov; 129(22):3620-3632. PubMed ID: 37382186
[TBL] [Abstract][Full Text] [Related]
30. Informed consent for exome sequencing in diagnostics: exploring first experiences and views of professionals and patients.
Rigter T; van Aart CJ; Elting MW; Waisfisz Q; Cornel MC; Henneman L
Clin Genet; 2014 May; 85(5):417-22. PubMed ID: 24117109
[TBL] [Abstract][Full Text] [Related]
31. Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research.
Middleton A; Morley KI; Bragin E; Firth HV; Hurles ME; Wright CF; Parker M;
Eur J Hum Genet; 2016 Jan; 24(1):21-9. PubMed ID: 25920556
[TBL] [Abstract][Full Text] [Related]
32. A Prospective Study of Parental Perceptions of Rapid Whole-Genome and -Exome Sequencing among Seriously Ill Infants.
Cakici JA; Dimmock DP; Caylor SA; Gaughran M; Clarke C; Triplett C; Clark MM; Kingsmore SF; Bloss CS
Am J Hum Genet; 2020 Nov; 107(5):953-962. PubMed ID: 33157008
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
34. Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.
Lee B; Tran B; Hsu AL; Taylor GR; Fox SB; Fellowes A; Marquis R; Mooi J; Desai J; Doig K; Ekert P; Gaff C; Herath D; Hamilton A; James P; Roberts A; Snyder R; Waring P; McArthur G
Intern Med J; 2018 Jul; 48(7):786-794. PubMed ID: 29607586
[TBL] [Abstract][Full Text] [Related]
35. A rural community's involvement in the design and usability testing of a computer-based informed consent process for the Personalized Medicine Research Project.
Mahnke AN; Plasek JM; Hoffman DG; Partridge NS; Foth WS; Waudby CJ; Rasmussen LV; McManus VD; McCarty CA
Am J Med Genet A; 2014 Jan; 164A(1):129-40. PubMed ID: 24273095
[TBL] [Abstract][Full Text] [Related]
36. Motivators for participation in a whole-genome sequencing study: implications for translational genomics research.
Facio FM; Brooks S; Loewenstein J; Green S; Biesecker LG; Biesecker BB
Eur J Hum Genet; 2011 Dec; 19(12):1213-7. PubMed ID: 21731059
[TBL] [Abstract][Full Text] [Related]
37. Canaries in the coal mine: Personal and professional impact of undergoing whole genome sequencing on medical professionals.
Zierhut H; McCarthy Veach P; LeRoy B
Am J Med Genet A; 2015 Nov; 167A(11):2647-56. PubMed ID: 26219924
[TBL] [Abstract][Full Text] [Related]
38. Precision oncology in the age of integrative genomics.
Kumar-Sinha C; Chinnaiyan AM
Nat Biotechnol; 2018 Jan; 36(1):46-60. PubMed ID: 29319699
[TBL] [Abstract][Full Text] [Related]
39. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.
Gallego CJ; Bennette CS; Heagerty P; Comstock B; Horike-Pyne M; Hisama F; Amendola LM; Bennett RL; Dorschner MO; Tarczy-Hornoch P; Grady WM; Fullerton SM; Trinidad SB; Regier DA; Nickerson DA; Burke W; Patrick DL; Jarvik GP; Veenstra DL
Contemp Clin Trials; 2014 Sep; 39(1):1-8. PubMed ID: 24997220
[TBL] [Abstract][Full Text] [Related]
40. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
